A switch to oxaliplatin and/or to anti-EGFR in the case of RAS wild-type tumour, or to other targeted therapies in the case of BRAF mutant tumour according to recent results,25 could be evaluated if the signal of early progression during induction is observed, and maintenance chemotherapy as 5FU or capecitabine plus bevacizumab combination could be compared with CFI if it was a signal of short CFI. This evidence concerns the gene EGFR and neoplasm.